1. 2022
  2. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma

    Thus, Y. J., Eldering, E., Kater, A. P. & Spaargaren, M., Sep 2022, In: Leukemia. 36, 9, p. 2165-2176 12 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  3. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment

    Chen, Z., Simon-Molas, H., Cretenet, G., Valle-Argos, B., Smith, L. D., Forconi, F., Schomakers, B. V., van Weeghel, M., Bryant, D. J., van Bruggen, J. A. C., Peters, F. S., Rathmell, J. C., van der Windt, G. J. W., Kater, A. P., Packham, G. & Eldering, E., 11 Aug 2022, In: Blood. 140, 6, p. 630-643 14 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. The Therapeutic Potential of Targeting NIK in B Cell Malignancies

    Haselager, M. V. & Eldering, E., 12 Jul 2022, In: Frontiers in immunology. 13, 930986.

    Research output: Contribution to journalReview articleAcademicpeer-review

  5. 2021
  6. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia

    Kater, A. P., Slinger, E., Cretenet, G., Martens, A. W., Balasubramanian, S., Leverson, J. D. & Eldering, E., 14 Dec 2021, In: Blood advances. 5, 23, p. 5410-5414 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Co-stimulatory versus cell death aspects of agonistic cd40 monoclonal antibody selicrelumab in chronic lymphocytic leukemia

    Delgado, R., Kielbassa, K., ter Burg, J., Klein, C., Trumpfheller, C., de Heer, K., Kater, A. P. & Eldering, E., 2 Jun 2021, In: Cancers. 13, 12, 3084.

    Research output: Contribution to journalArticleAcademicpeer-review

  8. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective

    Peters, F. S., Strefford, J. C., Eldering, E. & Kater, A. P., 1 May 2021, In: Haematologica. 106, 5, p. 1234-1243 10 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  9. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

    Haselager, M., Thijssen, R., West, C., Young, L., van Kampen, R., Willmore, E., Mackay, S., Kater, A. & Eldering, E., May 2021, In: Cell death and differentiation. 28, 5, p. 1658-1668 11 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  10. Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

    Slomp, A., Moesbergen, L. M., Eldering, E., Kersten, M. J., Minnema, M. C. & Peperzak, V., 1 Mar 2021, In: Cell death & disease. 12, 3, 229.

    Research output: Contribution to journalArticleAcademicpeer-review

  11. Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies

    Hofland, T., Martens, A. W. J., van Bruggen, J. A. C., de Boer, R., Schetters, S., Remmerswaal, E. B. M., Bemelman, F. J., Levin, M-D., Bins, A. D., Eldering, E., Kater, A. P. & Tonino, S. H., Mar 2021, In: European journal of immunology. 51, 3, p. 703-713 11 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  12. Kinase inhibitors developed for treatment of hematologic malignancies: Implications for immune modulation in COVID-19

    Jacobs, C. F., Eldering, E. & Kater, A. P., 9 Feb 2021, In: Blood advances. 5, 3, p. 913-924 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1 2 3 4 5 6 7 8 ...13 Next

ID: 54282